Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04863248 · ClinicalTrials.gov registry record · Phase 2
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
A Phase 2 study, sponsored by G1 Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04863248 is a Phase 2 study that was terminated before completion, run by G1 Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04863248, a Phase 2 study, was terminated before completion, sponsored by G1 Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Trilaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04863248
The ClinicalTrials.gov registry entry for NCT04863248 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is G1 Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04863248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04863248 about?
NCT04863248 is a clinical study titled "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)". This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.
What is the current status of trial NCT04863248?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-04-30. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT04863248?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Trilaciclib (DRUG).
Who is sponsoring clinical trial NCT04863248?
This trial is sponsored by G1 Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.